Method of preventing chronic toxic hepatopathy. RU patent 2468446.

FIELD: medicine.

SUBSTANCE: in order to prevent chronic toxic hepatopathy melaxen is introduced to animals in experiment one time per day in dose 10 mg/ml through probe into stomach. Simultaneously intragastric introduction of cobalt chloride solution in dose 2 mg/kg, in terms of metal, is performed daily, to create cobalt intoxication in organism.

EFFECT: method ensures efficient prevention of cobalt hepatopathy in conditions of selected modes of pathology modelling and melaxen introduction.

2 tbl, 2 dwg, 1 ex

IPC classes for russian patent Method of preventing chronic toxic hepatopathy. RU patent 2468446. (RU 2468446):

G09B23/28 - for medicine

A61P1/16 - for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

A61K31/4045 -

Another patents in same IPC classes:

Method for simulating abdominal commissures / 2467401
Invention refers to experimental medicine and may be used for simulating abdominal commissures. A blind intestine is injured by lengthwise notching by 1-1.2 cm of a seromuscular layer. A created wound of the blind intestine is closed by continuous single-layer extraluminal inverting suture. A parietal abdominal defect is created by scarification of its segment 1.5×1.5 cm in a right side area. A laparotomic wound is closed in layers by continuous suture.

Method for simulating treating patients with chronic spinal injury in laboratory animals / 2466756
Animal's spinal cord is completely cut at the level of an inferior thoracic segment. Stimulation is started 3 weeks after spinalisation. It is followed by electrical stimulation of the animal with the use of bipolar electrodes. Back extremities of the animal rest against a moving platform tape with the electrodes applied on animal's back or internal hip skin. Said zones are stimulated at frequency 5 Hz, pulse width 20 ms at intensity 1-10 mA.

Method for anaesthetisation in rats at staged experiment in simulated endometriosis / 2466753
What is involved is preanesthetic medication with xylazine. The preparation 'Zoletil 50' 0.5 mg/kg of rat's body weight is introduced intramuscularly for conducting main anaesthesia.

Method for pharmacological correction of extremity ischemia / 2466463
For the purpose of studying of the potential correction of ischemia, extremity ischemia is simulated in experimental animals. It is followed by the daily 28-day intragastric introduction of mixed solutions of homoeopathic dilutions of rabbit monoclonal antibodies to endothelial nitrogen oxide synthase -C12, C30, C200 4.5 ml/kg twice a day.

Method for placental microcirculation correction by recombinant erythropoietin in adma-like gestosis model / 2466462
Gestosis model in Wistar rats is reproduced by the daily intraperitoneal introduction of L-nitro-arginine-methyl ester 25 mg/kg for 14th to 20th day of pregnancy. The simulated pathology is corrected by the subcutaneous introduction of recombinant erythropoietin 50 IU/kg on the 7th, 10th, 13th, 16th, 19th day of pregnancy.

Method for simulating infected pancreatonecrosis / 2465655
Simulating infected pancreatonecrosis is ensured by inspection of an abdominal cavity with pancreas mobilisation. The pancreas is injured in a distal portion of a right lobe transversally through 3 cm with the use of Bilroth's hemostatic forceps for three times in various places. autobile 0.2 ml and the Acinetobacter baumannii clinical strain in the amount of 105 CFU/ml are introduced in a pancreatic parenchyma. Three days later, the animal is removed from the experiment; it is followed by blood and pancreatic tissue sampling and freezing at temperature 77°K. Electronic paramagnetic resonance is used to determine blood transferrin, ceruloplasmin and methemoglobin, pancreatic free iron, transferrin. If the values of methemoglobin and ceruloplasmin appear to increase to 0.16±0.05 standard units and 3.68±1.02 standard units respectively, the concentration of blood transferrin decreases to 0.83±0.24 standard units, while the level of free iron increases by 15 3 % and transferrin - by 206% as compared with the normal values, developing pancreatonecrosis is stated.

Method for simulating environment of replacing abdominal hernioplasty / 2465654
Wound defect is reduced in layers that involves forming fragments of hernioprosthesis composite coated with a polymer composite to be implanted in any layer of the wound subcutaneously or intraperitoneally. The hernioprosthesis represents a mesh of warp structure of synthetic polymer untwisted pneumatically coupled non thermally fixed complex filaments. The polymer composite consists of a substance of poviargol and medical polyvinylpyrrolidone. Molecular weight of medical polyvinylpyrrolidone makes 13000-90000D at the relation, wt %; 45-55 : 45-55.

Deep-etching method / 2464646
Solution containing the following ingredients is prepared: 40% fluohydric acid 220 g; zinc metal 100 g; ethylene glycol 800 g. A bone block with accepted titanium and titanium nickelide implants are immersed into the prepared solution.

Method for simulating global cerebral ischemia in small laboratory animals / 2464645
It involves reversible extracranial occlusion of supplying cerebral vessels, namely brachiocephalic artery, left subclavian artery and left common carotid artery within junction to the aortic arch. The length of an ischemic episode is determined by time of occlusion of said vessels by microvascular clips.

Method for simulating osteoarthrosis in temporomandibular joint / 2463669
Simulating osteoarthrosis of a temporomandibular joint is ensured by using the antithyroid preparation mercazolil (thiamazole) in the form of a water-starch suspension The preparation is introduced orally through a probe in dose 10.0-15.0 mg/kg of rat's body weight once a day. The preparation is introduced daily during 90 days.

Method for preparing agent showing cholagogue action / 2465000
Invention refers to pharmaceutical industry, specifically to an agent showing cholagogue action. A method for preparing the agent showing cholagogue action consisting in the fact that ground sandy everlasting blossom, nosebleed herb and peppermint leaves are mixed with coriander fruit, extracted in 40% ethanol by multistage counterflow extraction, settled, filtered, condensed under certain conditions.

Quinazoline derivative and pharmaceutical preparation / 2464263
Invention relates to a quinazoline derivative of general formula [1], or a pharmaceutically acceptable salt thereof [1], where R1-R6 assume values given claim 1, except compounds in which R5 is hydrogen and R6 is -NH2. The invention also relates to a pharmaceutical composition having the activity of an antipruritic agent, containing as an active ingredient said quinazoline derivative or pharmaceutically acceptable salt thereof.

Agent of saussurea ds plants possessing hepatoprotective action / 2464036
Invention refers to pharmaceutical industry, particularly to an agent possessing hepatoprotective activity and an ability to normalise the hepatic function. The use of a ground elevated part of Saussurea plants or an aqueous or aqueous-alcoholic or supercritical fluid extract of the elevated part of Saussurea plants as the agent possessing hepatoprotective activity and the ability to normalise the hepatic function.

Use of modified cyclosporines / 2463071
Group of inventions refers to medicine, particularly the use of non-immunosuppressive cyclophilin-binding cyclosporine for preventing or treating transplantation-related cirrhosis wherein cyclosporine (I) binds to human recombinant cyclophilin with a binding constant (BR) making less than 0.7 wherein BR represents a common logarithm of IC50 cyclosporine to IC50 cyclosporine A relation in concurrent experiment when evaluating by ELISA procedure; and (II) has activity in lymphocyte assay in the mixed culture making no more than 5% as compared with cyclosporine A activity (cl. 1) of the patent claim. There are also disclosed a pharmaceutical composition and a pharmaceutical combination containing cyclosporine under cl. 1.

Phospholipid nanoform for oral application (sachet) and method for preparing it (versions) / 2463057
Invention refers to medicine, pharmacology and concerns an oral granulated dosage form in sachets containing phospholipids in the form of particles of small (20-30 nm) diameter, glycyrrhizic acid and its salt (including sodium glycerrhizinate), as well as carbohydrate (including maltose) and excipients (granulation, anti-clotting and powder), as well as to a method for preparing it by mixing fat and water phases of herbal phospholipids and acceptable carbohydrate to prepare an emulsion, cooling to 50°C and passing through a microfluidiser for 4-5 cycles under pressure 2000 atm.

Agent showing hepatoprotective action, and method for preparing it / 2462259
Invention refers to pharmaceutical industry, specifically to an agent showing hepatoprotective action. The agent showing hepatoprotective action of a herbal polyphenol extract of Amur maackia heartwood (Maxar) which represents an aqueous solution of Maxar in the molecular-capsulated form in the form of a water-soluble associated with a surfactant having a specific hydrophilic-lipophilic balance. A method for preparing the agent showing hepatoprotective action by Maxar homogenisation in the melt surfactant under certain conditions to produce the molecular-capsulated form of the end product.

Method of treating patients with chronic liver diseases in stage of latency and degree i manifested stage of hepatic encephalopathy / 2462251
Invention refers to medicine and aims at treating the patients with chronic liver diseases (CLD) in the stage of latency and degree I manifested stage of hepatic encephalopathy. The preparation Essentiale forte N is used. It is combined with prescribing the preparation Mucofalk. The course is 28-30 days.

Method of treating chronic viral hepatitis c / 2459629
Invention refers to medicine, namely hepatology and may be applicable in treating chronic viral hepatitis C. That is ensured by introducing short-lived interferon-alpha (IFN) and the nucleoside analogue Ribamidil in the patient with an initial average week dosage specified in the range of 10.5 to 21.0 mil. IU depending on the level of native patient's interferon-alpha. Interferon-alpha is introduced with at least twice gradually increase of the average week dose to 21.0 to 84 mil. IU. Over the whole period of introducing IFN, the patient is prescribed with additional antiviral preparations - an interferon inducer, as well as an amantadin preparation or a glycyrrhizic acid preparation. It is combined with a support therapy involving the introduction of T-cell immunity stimulators and preparations for correction of side effects. The presence of blood viral ribonucleic acid is occasionally controlled and the introduction of Ribamidil is started in a daily dose of 800-1200 mg from the third month from the beginning of treatment if observing the presence of ribonucleic acid or from the tenth month if observing the absence. The treatment is continued until at least a 12-month aviremia period is achieved.

Method of prevention and treatment of liver disease with application of receptor a<sub>2b</sub> antagonists

Method of prevention and treatment of liver disease with application of receptor a_2b antagonists / 2457842
Group of inventions relates to field of medicine. Method of treatment and prevention of liver fibrosis includes peroral introduction to mammal of therapeutically efficient amount of antagonist of adenosine receptor A2B - 3-ethyl-1-propyl-8-(1-{[3-(trifluormethyl)phenyl]methyl}pyrazol-4-yl)-1,3,7-trihydropurine-2,6-dione. Method of reducing hepatotoxic side effects of chemical therapy or radiotherapy includes peroral introduction to mammal who underwent such treatment of therapeutically efficient amount of antagonist of adenosine receptor A2B - 3-ethyl-1-propyl-8-(1-{[3-(trifluormethyl)phenyl]methyl}pyrazol-4-yl) -1,3,7-trihydropurine-2,6-dione.

Granule and method for making thereof / 2456980
Invention refers to pharmaceutics. A pharmaceutical granule is spherical or spheroidal and has volume density 0.6-1.3 g/ml and disintegration 0.5-5 minutes. Active pharmaceutical ingredients are preparations of Traditional Chinese Medicine, herbal preparations or their extracts with a nucleus made of an extract of Traditional Chinese Medicine or herbal preparations, and a pharmaceutically acceptable carrier. The content of the pharmaceutically acceptable carrier with respect to total granule weight makes 10-60 wt %. The granule diameter can be equal to 700-1500 mcm. The granule nucleus diameter can be equal to 200-750 mcm. The granule can be also coated with a layer of 2-5 wt % with respect of total granule weight. A method for making the granules consists in introducing initial granules into a layer of a fluidised material as an excipient; the active pharmaceutical ingredients are prepared in the form of a suspension or a solution of the viscosity controlled within 6.0-9.8 MPa·s with using a viscosity-control agent; then they are sprayed over a surface of the initial granule for making a finished granule.

Method for correction of oxygenating pulmonary function / 2466748
Medical solution of serotonin adipinate is introduced endotracheally in the form of sprays or aerosols, by solution inhalations in the form of compressor or ultrasound nebulisers connected to a breathing system for artificial pulmonary ventilation, or by a syringe through a tracheostomic or endotracheal tube directly into a trachea through a bronchoscopic duct, or by puncture of a thyroid-cricoid membrane. The solution of serotonin adipinate contains serotonin adipinate 5 to 20 mg/ml as a main ingredient, and excipients presented by unitiol 1 mg/ml to 3 mg/ml and water for injections in an amount required to produce a pre-set percentage of the main ingredient and excipients.